David Grimwade

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

David Grimwade, Helen M. Walker, Fiona Oliver et al. · Blood · 1998 · 2.6K citations · Full text

Life Sciences, Hematology, Oncology +12

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 2K citations · Full text

Life Sciences, Hematology, Oncology +16

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

David Grimwade · Blood · 2001 · 918 citations · Full text

Life Sciences, Hematology, Oncology +14

Assessment of Minimal Residual Disease in Standard-Risk AML

Adam Ivey, Robert K. Hills, Michael A. Simpson et al. · New England Journal of Medicine · 2016 · 836 citations · Full text

Medicine, Hematology, Molecular Genetics +16

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · The Lancet Oncology · 2015 · 543 citations

Medicine, Hematology, Oncology +8